LIWANLI Innovation Co Ltd (3054) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LIWANLI Innovation Co Ltd (3054) has a cash flow conversion efficiency ratio of -0.056x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-41.53 Million ≈ $-1.31 Million USD) by net assets (NT$743.29 Million ≈ $23.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LIWANLI Innovation Co Ltd (3054) balance sheet quality index to measure how much of total assets are equity-financed.
LIWANLI Innovation Co Ltd - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how LIWANLI Innovation Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 3054 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
LIWANLI Innovation Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LIWANLI Innovation Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OM Holdings Ltd
KLSE:5298
|
-0.004x |
|
Pioneer Floating Rate Trust
NYSE:PHD
|
0.054x |
|
Land General Bhd
KLSE:3174
|
0.065x |
|
Stalexport Autostrady SA
WAR:STX
|
-0.104x |
|
Impiana Hotels Bhd
KLSE:7243
|
-0.032x |
|
Chongkundang
KO:001630
|
0.029x |
|
Shanghai Huayi Group Corp Ltd B
SHG:900909
|
-0.074x |
|
Harmony Electronics
TWO:8182
|
-0.019x |
Annual Cash Flow Conversion Efficiency for LIWANLI Innovation Co Ltd (2005–2024)
The table below shows the annual cash flow conversion efficiency of LIWANLI Innovation Co Ltd from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see LIWANLI Innovation Co Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$752.96 Million ≈ $23.72 Million |
NT$14.20 Million ≈ $447.44K |
0.019x | +129.36% |
| 2023-12-31 | NT$783.51 Million ≈ $24.68 Million |
NT$-50.34 Million ≈ $-1.59 Million |
-0.064x | -162.66% |
| 2022-12-31 | NT$765.36 Million ≈ $24.11 Million |
NT$78.48 Million ≈ $2.47 Million |
0.103x | +250.54% |
| 2021-12-31 | NT$897.52 Million ≈ $28.28 Million |
NT$-61.13 Million ≈ $-1.93 Million |
-0.068x | -74.07% |
| 2020-12-31 | NT$936.03 Million ≈ $29.49 Million |
NT$-36.63 Million ≈ $-1.15 Million |
-0.039x | +65.38% |
| 2019-12-31 | NT$965.79 Million ≈ $30.43 Million |
NT$-109.16 Million ≈ $-3.44 Million |
-0.113x | +5.90% |
| 2018-12-31 | NT$1.02 Billion ≈ $32.29 Million |
NT$-123.09 Million ≈ $-3.88 Million |
-0.120x | -291.91% |
| 2017-12-31 | NT$1.53 Billion ≈ $48.34 Million |
NT$96.03 Million ≈ $3.03 Million |
0.063x | -15.97% |
| 2016-12-31 | NT$1.51 Billion ≈ $47.66 Million |
NT$112.68 Million ≈ $3.55 Million |
0.074x | +138.61% |
| 2015-12-31 | NT$1.09 Billion ≈ $34.36 Million |
NT$34.04 Million ≈ $1.07 Million |
0.031x | -91.83% |
| 2014-12-31 | NT$1.24 Billion ≈ $39.01 Million |
NT$473.04 Million ≈ $14.90 Million |
0.382x | +686.36% |
| 2013-12-31 | NT$1.38 Billion ≈ $43.43 Million |
NT$-89.82 Million ≈ $-2.83 Million |
-0.065x | +52.82% |
| 2012-12-31 | NT$753.19 Million ≈ $23.73 Million |
NT$-104.02 Million ≈ $-3.28 Million |
-0.138x | +30.01% |
| 2011-12-31 | NT$799.59 Million ≈ $25.19 Million |
NT$-157.77 Million ≈ $-4.97 Million |
-0.197x | -325.30% |
| 2010-12-31 | NT$895.33 Million ≈ $28.21 Million |
NT$78.41 Million ≈ $2.47 Million |
0.088x | +9.91% |
| 2009-12-31 | NT$1.12 Billion ≈ $35.36 Million |
NT$89.43 Million ≈ $2.82 Million |
0.080x | +4.20% |
| 2008-12-31 | NT$666.68 Million ≈ $21.00 Million |
NT$50.98 Million ≈ $1.61 Million |
0.076x | -3.33% |
| 2005-12-31 | NT$462.99 Million ≈ $14.59 Million |
NT$36.62 Million ≈ $1.15 Million |
0.079x | -- |
About LIWANLI Innovation Co Ltd
LIWANLI Innovation Co., Ltd. operates in the biomedical science industry in Taiwan and internationally. The company offers Vigoway and powder collection products for male, female, elderly, and children. Its products include anti-aging desire, pro-active nutrients capsules, black elderberry powder, probiotic enzymes, oral care tablets, resveratrol red grape extract, algae DHA soft gels, shea butte… Read more